Moreover, in HER2 positive BC, the response to HER2-targeted therapy could be modulated by the level of HER2 heterogeneity, defined as an area with ERBB2 amplification in >5% but <50% of tumor cells, or a HER2 negative area by FISH. This evidence concerns the gene ERBB2 and neoplasm.